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Background: Molecular mechanisms associated with frequent relapse of diffuse large B-cell lymphoma (DLBCL) are
poorly defined. It is especially unclear how primary tumor clonal heterogeneity contributes to relapse. Here, we explore
unique features of B-cell lymphomas - VDJ recombination and somatic hypermutation - to address this question.
Results: We performed high-throughput sequencing of rearranged VDJ junctions in 14 pairs of matched
diagnosis-relapse tumors, among which 7 pairs were further characterized by exome sequencing. We identify
two distinctive modes of clonal evolution of DLBCL relapse: an early-divergent mode in which clonally related
diagnosis and relapse tumors diverged early and developed in parallel; and a late-divergent mode in which
relapse tumors developed directly from diagnosis tumors with minor divergence. By examining mutation
patterns in the context of phylogenetic information provided by VDJ junctions, we identified mutations in
epigenetic modifiers such as KMT2D as potential early driving events in lymphomagenesis and immune escape
alterations as relapse-associated events.
Conclusions: Altogether, our study for the first time provides important evidence that DLBCL relapse may result
from multiple, distinct tumor evolutionary mechanisms, providing rationale for therapies for each mechanism.
Moreover, this study highlights the urgent need to understand the driving roles of epigenetic modifier
mutations in lymphomagenesis, and immune surveillance factor genetic lesions in relapse.Background
Diffuse large B-cell lymphoma (DLBCL) is an aggressive
form of non-Hodgkin’s lymphoma in which one-third of
patients either do not respond to initial therapy or re-
lapse after standard therapy, such as dose-dense or
standard immunochemotherapy with rituximab and
cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) [1]. Although relapses normally occur early
(first 2 to 3 years), some do occur after 5 years [2].
Treatment options for relapse and refractory DLBCLs
are limited and only 10% of the relapsed patients achieve
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unless otherwise stated.underlying the urgent need for novel approaches to
treat DLBCL relapse [3,4]. Unfortunately, our current
understanding of the molecular mechanisms associated
with DLBCL relapse is limited. It is, for example, unclear
whether genetic mutations present in the tumor at diag-
nosis or acquired after treatment help certain DLBCL cell
populations to acquire resistance to treatment. More gen-
erally, it is presently unclear whether clonal heterogeneity
in primary tumors plays a role in DLBCL relapse.
Previously, Ding et al. [5] examined genetic changes
associated with acute myeloid leukemia relapse using
whole-genome sequencing and used patterns of mutational
abundances to infer clonal evolution patterns. However,
due to the lack of tractable markers on myeloid cells, it is
difficult to precisely and definitely deduce clonal evolution
patterns between diagnosis and relapse acute myeloid leu-
kemias. The situation is potentially different in lymphoid
malignancies originating from mature B cells, since thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(or VJ) junctions. Indeed, in order to generate a diversified
repertoire of antibodies, each B cell undergoes somatic
immunoglobulin heavy chain (IGH) VDJ recombination at
the pro B-cell stage to create a single productive VDJ
junction from a large pool of VH (variable), D (diversity),
and JH (joining) segments. In addition, during this process,
non-templated nucleotides (N-bases) may be added at
the junctions, and a small part of the VH, D, JH germline
sequences may be deleted, resulting in a unique VDJ
rearrangement, which effectively tags each B cell and its
progeny [6]. In the subsequent germinal center (GC) reac-
tion, B cells further introduce point mutations into the
recombined VDJ sequences, a process known as somatic
hypermutation (SHM), to enhance antibody affinity [7,8].
Because DLBCLs arise from GC or post-GC B cells, we
hypothesized that their clonal populations can be
tracked by their VDJ and SHM patterns to reveal valu-
able information regarding intra-tumor heterogeneity and
clonal evolution of the disease. To test this hypothesis,
we performed high-throughput sequencing of rearranged
VDJ junctions in 14 pairs of matched primary diagnosis-
relapse DLBCLs and discovered two distinct clonal
evolutionary scenarios of DLBCL relapse. Furthermore,
in conjunction with exome sequencing on several
diagnosis-relapse pairs, we identified mutations within
histone-modifying enzymes as candidate early drivers
in DLBCL lymphomagenesis, and genetic lesions in
immune surveillance genes as potential facilitators in
DLBCL relapse.
Results
Deep VDJ sequencing revealing clonal heterogeneity
of DLBCL
To trace the clonal identities of the diagnosis-relapse
DLBCL pairs (N = 14, patient information summarized
in Additional file 1), we performed Illumina MiSeq
PE 2 × 150 bp sequencing on the 300 to 350 bp PCR
products targeting the genomic IGH VDJ sequences
(see Materials and methods). We reasoned that long
reads generated using this approach should enable
phylogenetic analysis based on SHM mutation patterns.
We generated 0.38 to 1.42 million paired-end reads/sample
(average 0.75 ± 0.26 million; Additional file 2). We developed
a custom bioinformatics pipeline to align each paired-end
read to germline immunoglobulin V, D, and J sequences in
the IMGT database [9] and annotate the recombined VDJ
junctions (see Materials and methods). The average align-
ment rate was 67.7 ± 14.1% (Additional file 2). In total, we
identified 0.28 to 0.93 million (average 0.49 ± 0.15 million)
VHDJH junctions per sample (Additional file 2), and
the numbers of aligned reads were comparable be-
tween diagnosis and relapse samples within each pair
(Figure S1 in Additional file 3).We first sought to examine the VHDJH heterogeneity of
each individual tumor (diagnosis or relapse) and counted
how many times each combination of VH, D, and JH was
found. We found, on average, 7.4 distinct VHDJH junc-
tions per thousand mapped paired-end reads per sample
(Table 1). However, the number of unique rearrangements
per sample ranged broadly from 0.5 to 27.1 per thousand
mapped paired-end reads, indicating high VDJ hetero-
geneity within DLBCL samples, similar to what has been
reported in acute B lymphoblastic leukemia (B-ALL)
[10]. There was no significant difference in number of
unique rearrangements per thousand mapped paired-end
reads between the paired diagnosis and relapse samples
(6.6 ± 7.5 versus 6.2 ± 6.9, P = 0.85, paired t-test; or P = 0.80,
Wilcoxon matched pairs test; Figure S2 in Additional file 3).
For each sample, there was either one or two dominant
VHDJH rearrangements that together account for 65%,
on average, of all the identified VHDJH sequences, likely
representing the productive and nonproductive alleles
of the major tumor subclone [11] (Table 1). The other less
abundant VHDJH rearrangements were likely representing
either VHDJH sequences with high SHM rates that could
not be readily mapped to major tumor VHDJH sequences,
or benign B-cell infiltration within the DLBCL tumors. To
further address this question, we decided to compare the
clonal distribution frequency between the tumor and nor-
mal B-cell populations by performing VDJ sequencing on
a bone marrow (BM) B-cell sample and tumor sample
from one DLBCL patient. Although tumor cell infiltration
was observed in the BM sample (approximately 1.1% of
the total VHDJH sequences), most VHDJH sequences did
not match the tumor VHDJH and therefore correspond to
normal non-malignant B cells. We observed that the
major dominant VHDJH rearrangements only accounted for
1.5% in the BM sample, similar to what has been reported
previously for normal B cells [12]. Thus, the dominant
VHDJH rearrangements we observed in tumor samples
are not compatible with normal B-cell clonal expansion
and indeed represent the malignant B-cell populations
in these tumors. Furthermore, when we excluded the
dominant VHDJH rearrangements from the tumor sam-
ple (the tumor rearrangement) and then compared the
distribution of the remaining VHDJH rearrangements of
the tumor sample to the BM sample, we observed similar
distribution frequencies (Figure S3 in Additional file 3),
indicating that these minor VHDJH rearrangement clones
were indeed likely representing infiltrating non-malignant
normal B-cell populations (VHDJH sequence mapping
errors due to high SHM rates cannot be completely ex-
cluded). The diagnosis and relapse tumors of all but one
pair (pair 6) harbored the same major VHDJH rearrange-
ment, demonstrating that they were clonally related regard-
less of the length of time it took the relapse to develop
(Table 1). Accordingly, the relapse tumors of late-relapse
Table 1 Summary of VHDJH sequencing results
Pair number Sample
ID




per 103 mapped reads











1 1D Diagnosis 311 0.69 IGHV4-34 IGHD3-22 IGHJ5 96.9% 1,591 3.60
1R1 Relapse 265 0.50 IGHV4-34 IGHD3-22 IGHJ5 94.9% 2,109 4.07
1R2 Relapse NA NA NA NA NA NA
1R3 Relapse 396 0.66 IGHV4-34 IGHD3-22 IGHJ5 94.5% 2,487 4.26
2 2D Diagnosis 315 0.72 IGHV4-59 IGHD6-19 IGHJ5 82.2% 1,963 4.53
2R1 Relapse 3,131 7.27 IGHV4-59 IGHD6-19 IGHJ5 88.9% 1,372 3.44
2R2 Relapse NA NA NA NA NA NA
3 3D1 Diagnosis 950 1.84 IGHV3-49 IGHD2-8 IGHJ4 28.3% 421 2.81
IGHV3-49 IGHD3-22 IGHJ4 27.0% 596 2.13
3R2 Relapse 745 1.29 IGHV3-49 IGHD3-22 IGHJ4 29.2% 608 2.41
IGHV3-49 IGHD2-8 IGHJ4 28.0% 781 3.17
4 4D Diagnosis 9,158 23.08 IGHV3-7 IGHD4-17 IGHJ6 69.7% 1,318 4.75
4PR Progression 1,785 4.34 IGHV3-7 IGHD4-17 IGHJ6 43.0% 933 5.23
5 9D Diagnosis 2,911 4.27 IGHV4-34 IGHD6-13 IGHJ6 47.5% 1,381 4.16
IGHV1-18 IGHD6-13 IGHJ2 39.6% 1,075 3.96
9R Relapse 18,683 25.72 IGHV1-18 IGHD6-13 IGHJ2 9.2% 328 4.57
IGHV4-34 IGHD6-13 IGHJ6 3.5% 154 5.33
6 12D Diagnosis 7,570 22.12 IGHV3-74 IGHD4-17 IGHJ4 25.2% 0 0
12R Relapse 7,299 13.78 IGHV3-23 IGHD6-13 IGHJ4 24.1% 496 3.86
7 13D1 Diagnosis 7,931 27.09 IGHV3-23 IGHD3-9 IGHJ6 82.4% 870 5.14
13D2 Diagnosis 2,436 6.65 IGHV3-23 IGHD3-9 IGHJ6 89.6% 718 5.74
13R Relapse 1,204 3.71 IGHV3-23 IGHD3-9 IGHJ6 93.1% 858 5.27
8 14D Diagnosis 4,172 12.07 IGHV1-18 IGHD6-13 IGHJ2 48.0% 819 4.89
IGHV4-34 IGHD6-13 IGHJ6 24.1% 327 3.76
14R Relapse 1,206 3.84 IGHV1-18 IGHD6-13 IGHJ2 57.7% 883 4.81
IGHV4-34 IGHD6-13 IGHJ6 32.1% 421 3.96
9 15D1 Diagnosis 8,727 15.47 IGHV1-18 IGHD6-13 IGHJ2 23.7% 471 4.97
IGHV3-48 IGHD2-2 IGHJ4 26.8% 0 0
15D2 Diagnosis 955 2.83 IGHV1-18 IGHD6-13 IGHJ2 37.3% 18 2.73
IGHV4-34 IGHD6-13 IGHJ6 35.4% 0 0















Table 1 Summary of VHDJH sequencing results (Continued)
IGHV1-18 IGHD6-13 IGHJ2 33.5% 471 5.00
10 16D Diagnosis 11,303 12.10 IGHV1-18 IGHD6-13 IGHJ2 55.2% 867 1.61
16R Relapse 1,875 2.67 IGHV1-18 IGHD6-13 IGHJ2 44.8% 1,079 3.42
11 F6D Diagnosis 786 1.04 IGHV3-23 IGHD3-22 IGHJ4 72.5% 991 4.22
F6PR Progression 2,135 4.03 IGHV3-23 IGHD3-22 IGHJ4 61.0% 1,245 5.29
12 F7D Diagnosis 3,491 6.07 IGHV4-34 IGHD3-22 IGHJ6 45.2% 231 0.61
F7R Relapse 6,115 14.58 IGHV4-34 IGHD3-22 IGHJ6 40.0% 82 0.33
13 SPF6-1 Diagnosis 1,160 2.41 IGHV3-7 IGHD3-10 IGHJ4 90.0% 1,691 3.83
SPF6-2 Diagnosis 828 1.75 IGHV3-7 IGHD3-10 IGHJ4 93.1% 1,854 3.93
SPF6-3 Relapse 719 1.54 IGHV3-7 IGHD3-10 IGHJ4 95.8% 1,754 3.85
14 SPF10-1 Diagnosis 1,463 3.17 IGHV3-49 IGHD3-10 IGHJ5 67.8% 1,425 3.65
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initial diagnosis (pairs 1, 8, 9, 12; Additional file 1) still car-
ried the same VHDJH rearrangements as their respective
diagnosis tumors.
Two scenarios of DLBCL relapse clonal evolution
We further focused our analysis on the major VHDJH
rearrangement identified in each tumor. In addition to
VHDJH rearrangement, DLBCL cells have undergone
various degrees of SHM within the rearranged VHDJH se-
quences, which can in theory be further utilized to delineate
the subclonal population structure of the tumor. Indeed,
we identified unique subclones (found at least 10 times)
with distinctive SHM patterns within the dominant VHDJH
sequence of each sample (Table 1). Diagnosis samples had,
on average, 3.6 ± 1.4 subclones per thousand mapped major
VHDJH rearrangements. Relapse tumors had 4.1 ± 1.3
subclones per thousand mapped major VHDJH rearrange-
ments. There was no significant difference in the subclone
frequency between the relapse and diagnosis samples
(P = 0.07, two-tailed paired t-test; or P = 0.17, Wilcoxon
matched pairs test; Figure S4 in Additional file 3). We
then observed that eight pairs of samples had increased
normalized subclone numbers in relapse samples, while
five pairs had decreased normalized subclone numbers in
relapse samples compared with their respective diagnosis
samples (Figure S4 in Additional file 3; we excluded pair 6
in this and subsequent VDJ subclone analyses due to un-
matched dominant VDJ between diagnosis and relapse
samples), suggesting that the clonal subpopulation change
is a dynamic process during DLBCL relapse.
We then sought to use the subclone SHM information to
trace the clonal evolution of each sample pair. As described
in Materials and methods, we performed phylogenetic ana-
lysis of the SHM profiles of the major VHDJH rearrange-
ments between each diagnosis and relapse pair using the
neighbor joining phylogenetic tree reconstruction approach
[13]. This analysis uncovered two distinct scenarios of
DLBCL relapse (Figure 1A; Figure S5 in Additional file 3).
In one scenario (scenario I, n = 6, pairs 1, 2, 4, 5, 9, 10),
the major relapse clones clustered in a separate branch
from the diagnosis clones on the phylogenetic tree
(Figure 1A; Figure S5A,B,D,E,H,I in Additional file 3). The
relapse clones clustered either alone (n = 2, pairs 4 and 9)
or together with a highly divergent minor diagnosis clone
(n = 4; Figure 1A; see the small blue clone (third bar above
the major relapse clone) clustered together with the red
clones within the top branch). This particular pattern
indicates that, in this scenario, although the relapse and
diagnosis tumors were derived from the same B cell
(they share the same VHDJH rearrangement and several
somatic hypermutations), their precursors have diverged,
acquired different mutations within VHDJH sequences
(Figure 1A, right panel), and expanded at differenttimes. Moreover, that the major relapse clones frequently
cluster with a minor divergent clone found at diagnosis
suggest that preexisting, chemoresistant and divergent
diagnosis subclones are capable of eventually regenerating
entire relapse tumors.
In the second scenario (scenario II, n = 7, pairs 3, 7, 8,
11, 12, 13, 14), the dominant diagnosis and relapse clones
clustered together very closely (Figure 1B, left panel), with
similar SHM patterns. The dominant clones in the diag-
nosis and relapse tumor share the vast majority of the
IgVH somatic mutations, with only one or few different
mutations in the relapse tumor that could not differentiate
them into separate branches (Figure 1B, right panel;
Figure S5C,F-G,J-M in Additional file 3). This observa-
tion is compatible with a scenario where the relapse tu-
mors arise linearly from the major diagnosis clone or
from a highly related subclone that appears to be more
abundant in the diagnosis tumor compared with the
former scenario.
Due to unequal starting amounts of DNA, our VDJ
sequencing libraries produced variable numbers of
reads as indicated in the previous section. To make
sure that VDJ sequencing depth would not affect our
clonal evolution analysis, we sequenced two pairs of
samples (one from scenario I (pair 10) and one from
scenario II (pair 3)) to a very high depth (approximately
two million paired reads per sample) compared with our
original analysis, and then systematically subsampled
the reads with decreasing rates (1/10th each round) to
assess the VDJ recombination composition. We found that
although the major VDJ frequency remained the same
across all sample rates and for each sample (Figure S6A in
Additional file 3), we did observe increased numbers of
subclones with increasing sequencing depth (Figure S6B
in Additional file 3). When we constructed phylogenetic
trees of the subclones discovered at different subsampling
levels for these two samples, we found that the relapse
clonal evolution patterns did not change with increased
number of subclones between the range of 10,000 to
1,000,000 reads (Figure S6C in Additional file 3), within
which our original VDJ sequencing depth occurred, sug-
gesting that the slight difference in VDJ sequencing depth
across our samples would not undermine the accuracy of
our relapse clonal evolution analysis.
We next examined the mutational distance between
the major clones within the diagnosis and the relapse
pairs. We found that divergent scenario (scenario I)
diagnosis-relapse pairs had significantly more SHMs in
the relapse samples and the SHMs occurred at differ-
ent sites compared with diagnosis samples (P = 0.03,
Wilcoxon matched pairs test). On the other hand, sam-
ple pairs of the less divergent scenario (scenario II) had
less difference in SHM number and location between the
relapse and diagnosis when compared with the divergent
Figure 1 Two scenarios of DLBCL relapse. (A,B) Phylogenetic analysis of the SHM profiles of sample pair 1 showing the early-divergent relapse
mode (A), and sample pair 3 showing the late-divergent relapse mode (B). The length of the blue and red lines in the phylogenetic trees
indicates the number of VDJ sequences with a particular SHM profile. The SHM profiles of the major VDJ subclones of the diagnosis and relapse
samples are shown on the right with color tickers representing the mutation status. (C) Mutational distance between the major clones within the
diagnosis and the relapse pairs. (D) The frequencies of the major diagnosis subclone in the diagnosis sample and the respective relapse sample
of each sample. (E) Empirical entropy for the major VHDJH was calculated for each diagnosis tumor sample, and the average of the estimated
entropy was compared between the divergent mode samples and relapse mode samples.
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Figure 1C).
Moreover, when we traced the fate of the major diagnosis
subclone within the relapse tumor, we found that theyalmost disappeared in the relapse tumors of the more diver-
gent mode pairs (scenario I; Figure 1D). On the contrary,
the major diagnosis subclone maintained the same relative
abundance in the relapse tumors of the less divergent cases
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of the less divergent cases (scenario II) behaved similarly to
the more divergent cases (scenario I), namely sample pairs
7 and 13 (Figure 1D). We plotted the relapse subclone
frequencies according to their distance from the major
diagnosis subclones (number of SHMs different from
the major diagnosis subclone) and found that, in these
two pairs, the entire major relapse subclones differed in
only one or two mutations compared with their respect-
ive diagnosis subclones (Figure S7 in Additional file 3).
Therefore, the abundance of the major diagnosis sub-
clone decreased to almost 0 at relapse in these samples.
We performed the same analysis on the more divergent
sample pairs (scenario I), and found that the difference in
SHM pattern between the major diagnosis and relapse
subclones was much greater (pairs 2 and 9, for example;
Figure S7 in Additional file 3).
Based on these VDJ SHM analyses, two patterns emerge
that differ in the degree of divergence (from the major
diagnosis subclones) of the tumor clones from which the
relapse tumors were derived. The first mode (scenario I)
demonstrates a distinct divergence; the diverged subclone
is present as a very minor subclone in the diagnosis tumor
in some cases and appears to arise earlier in the diagnosis
tumor during tumor evolution. We termed scenario I
the early-divergent mode. The second mode (scenario II)
does not show a distinct divergence and suggests that
the relapse tumor may be derived from a subclone that
is more closely related to the major diagnosis subclone
(often more abundant) at a relatively late stage during
tumor evolution. We therefore named scenario II the
late-divergent mode. The presence of two modes of
relapse, early-divergent (scenario I) or late-divergent
(scenario II), can be further confirmed by whole exome
sequencing (see below).
Diagnosis tumors with early-divergent evolution to
relapse show increased clonal heterogeneity compared
with tumors with late-divergent evolution
We examined whether the two relapse modes identified
in this study were correlated with clinical features of
DLBCL. By performing immunohistochemistry on BCL6,
CD10, and MUM1 (Hans classification), we were able to
determine the subtypes of these samples (GCB-DLBCL
versus non-GCB-DLBCL; Additional file 1). We found
the time to relapse was significantly higher in GCB-DLBCL
compared with non-GCB-DLBCL (P = 0.02, Mann–
Whitney test). However, when we examined the relation-
ship between disease subtypes and relapse modes, we found
that both subtypes were evenly distributed between the two
relapse modes (chi-square test P = 0.55), indicating that
there is no correlation between DLBCL subtypes and re-
lapse clonal evolution. We also compared the average
time to relapse and did not find significant differencebetween the two modes of relapse (3.2 ± 1.5 years versus
3.0 ± 1.0 years, late-divergent versus early-divergent,
P = 0.74, Mann–Whitney test). We then investigated
whether clonal heterogeneity at diagnosis could predict
which scenario towards relapse (early or late divergent) a
patient was most likely to follow. We examined the pat-
tern of subclones with distinctive SHM patterns within
the dominant VHDJH sequence of each sample, and used
the frequency with which each subclone appeared to
calculate the empirical entropy for the major VHDJH of
each diagnosis tumor sample. Empirical entropy mea-
sures the diversity of SHM patterns found in each sample,
with higher entropy corresponding to higher diversity
(see Materials and methods). We found that although
entropy did not correlate with time to relapse (Figure S8
in Additional file 3), the early-divergent samples had, on
average, statistically significantly higher entropy than the
late-divergent cases at diagnosis (Figure 1E; P = 0.005,
Student’s t-test; or P = 0.02, Mann–Whitney test). These
analyses indicate that, overall, diagnosis tumors that
evolve according to the early-divergent scenario have a
more diverse pattern of subclones at diagnosis. This
observation is compatible with the observation made
above that a minor, highly divergent subclone likely
gives rise to the relapse tumor in the early-divergent
scenario. It does suggest, however, that in such diver-
gent scenarios, many other divergent clones exist at
diagnosis besides the one that gives rise to relapse.
Distinctive genetic evolution patterns of the two
relapse scenarios
To further investigate these evolutionary scenarios, we
performed exome sequencing of seven pairs of diagnosis
and relapse tumors for which we had sufficient materials
(three late-divergent, three early-divergent, and one with a
different major VDJ (pair 6); Additional file 2). We achieved
65 ± 17X sequencing depth on average and at least 20X
depth on 81.7 ± 7.8% of the region targeted. We performed
single nucleotide variants (SNVs) calling using a previously
published procedure [14-16]. We directly compared each
relapse sample to its matched diagnosis tumor to identify
gained or lost coding region nonsynonynmous SNVs at re-
lapse (SNVs within copy number alteration (CNA) regions
were excluded; Figure 2A; Additional file 4). The direct
comparison between the matching diagnosis and relapse
samples provides several advantages: first, it enabled us
to identify genetic alterations only associated with the
relapse process of each patient; and second, it allowed
us to exclude the majority of the individual specific
SNPs (that are not in SNP databases such as dbSNP)
without sequencing somatic control DNA, which the
historical surgical pathology specimens often lack. In-
deed, for three patients for whom there were sufficient
amounts of high quality material, we performed exome
A.












































































































































Figure 2 Different patterns of SNV gain and loss between the early and late-divergent modes. (A) SNV profile of each sample pair. (B) The
ratio of the numbers of gained and lost SNVs between each relapse and diagnosis sample pair was calculated. The average and standard error of
the ratio for each relapse mode are presented.
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pair 2, 3C of sample pair 3, and 13C of sample pair 7;
Additional file 2), and found that 90.4% of gained and
lost coding region nonsynonymous SNVs identified in
their respective tumor samples were not mutated in the
somatic control DNA. Of note is that our analysis focused
on SNVs whose allelic frequency changes significantly be-
tween diagnosis and relapse (in either direction). We used
Fisher exact with 10% false discovery rate control to deter-
mine significance. This analysis does not remove variants
whose allelic frequency changes significantly between
diagnosis and relapse but that are nonetheless present
in germline. Since it is not impossible that these vari-
ants contribute to some aspects of the disease, we left
them in the analysis. In addition, we performed Sanger
sequencing on the remaining three sample pairs whose
somatic control DNA was in low quantities that it was
not suitable for exome study (1C of sample pair 1, 2C
of sample pair 2, and 15C of sample pair 9). We ran-
domly selected 37 SNVs from these three samples to
validate and 94.6% them (35 out of 37) were confirmed
to be somatic (Additional file 5). These results validate
our approach as a robust method to identify specific
disease-associated mutations in tumor samples even in
the absence of germline controls. We found that overall re-
lapse samples gained coding region nonsynonymous SNVs
in 305 genes, among which only 71 were mutated in other
previously reported primary DLBCL genomic sequencing
studies, including BCL2, EP300, KMT2D, MYC, TET2, and
TNFRSF14 [17-20]. We also found one late-divergent mode
patient (pair 8, sample ID 14R) with relapse-specific
EZH2Y641 mutation (Figure 2A), indicating that relapseDLBCL can also acquire new EZH2 mutations and that, in
addition to its roles in initiating and maintaining DLBCL
[21], mutant EZH2 may also contribute to disease relapse.
For patient 1, we were able to obtain biopsies from three
different relapse sites (Additional file 1). We compared the
coding region nonsynonymous SNVs gained in these three
relapse samples with the original diagnosis sample and
found all of them gained mutations in BET1L, GNAS, and
UBR4 genes, suggesting these mutations may be respon-
sible for the initial transformation to relapse disease. Inter-
estingly, relapse tumors 1R2 and 1R3 had more overlapping
mutations, indicating that these two relapse tumors were
more clonally related than they were to 1R1. The numbers
of gained and lost SNVs between diagnosis and relapse
samples were variable among patients (Additional file 4).
On average, the late-divergent relapse samples gained
44.3 ± 17.6 SNVs and lost 7.5 ± 1.9 SNVs compared with
their diagnosis samples; in contrast, the early-divergent
relapse samples gained 32.0 ± 5.6 and lost 35.8 ± 6.6
SNVs. The late-divergent scenario relapse samples gained
roughly four times more coding region nonsynonymous
SNVs than they lost compared with their respective
diagnosis samples (5.2 ± 1.9-fold; Figure 2B), represent-
ing the continuous alteration of the tumor genome
with additional mutations acquired to achieve relapse.
On the contrary, the early-divergent scenario relapse
samples gained and lost approximately equal numbers
of coding region nonsynonymous SNVs compared with
the diagnosis samples (1.4 ± 0.7-fold; Figure 2B). The
coding region nonsynonymous SNV spectrums of the
relapse-diagnosis pairs confirm the two tumor evolu-
tion modes uncovered by VDJ sequencing. Tumors in
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of their diagnosis and relapse DLBCL genome early during
tumor development and therefore acquire new genomic
mutations independently and share fewer mutations in
common (that is, appear to lose more SNVs). Whereas in
the late-divergent scenario, relapse tumors originate from
subclones generated during the late stage of tumor evolu-
tion and therefore share more mutations in common with
the diagnosis tumors (that is, appear to lose fewer SNVs).
The presence of 'lost' SNVs in the relapsed tumor com-
pared with the diagnosis tumors within the late-divergent
category argues against a 'direct evolution' scenario in which
the relapse tumors are generated directly from the major
diagnosis subclone. If that had been the case, the relapsed
tumors should have shown no lost SNVs.
Immune surveillance genes are specifically targeted by
indels and deletions in relapse
In addition to coding region nonsynonymous SNVs, we
identified 39 small indels gained in relapse samples that
targeted the coding regions of 36 genes (Additional file 6).
On average, each relapse sample gained 5.2 ± 3.8 indels.
Moreover, we identified CNAs by comparing each relapse
exome with its respective diagnosis exome. We identified
CNA segments specific to each relapse sample by using a
previously widely used and validated R package, DNAcopy
[22,23] applied to sequencing depth-adjusted relapse
versus diagnosis read count log ratios (Figure S9 in
Additional file 3; see Materials and methods). Some
CNAs span large chromosome regions, while some are
focal alterations (Figure 3; Additional file 7). On average,
relapse tumors acquired 55.6 ± 6.8 CNAs, including
25.0 ± 5.0 amplifications and 30.6 ± 3.5 deletions. We
did not detect CNAs that were common to all the
relapse samples. However, we observed several loci that
were deleted in multiple relapse samples compared with
their respective diagnosis samples (Table 2). We validated
two such loci by TaqMan copy number assays, both of
which showed loss of genetic material in the relapse
samples compared with their respective diagnosis samples
(Figure S10 in Additional file 3). These commonly de-
leted regions harbor genes that are potentially important
for B-cell development and malignant transformation
(Table 2). For example, three relapse samples (1R3, 3R, 14R)
had a relapse-specific deletion spanning CD58, a gene
that has been shown to be genetically altered in a subset
of DLBCLs [24]. Furthermore, 14R had a relapse specific
frameshift indel within the remaining allele of the CD58
gene (Additional file 6). Alteration of this gene may help
tumor B cells to escape immune surveillance mecha-
nisms [24]. In addition to CD58 deletion in these three
relapse samples, we also found that samples 1R2 and
14R gained coding region nonsynonymous SNVs in
B2M (Additional file 4), another gene that is involved inimmune surveillance escape [24]. There was also a
relapse-specific frameshift indel within B2M in sample
15R (Additional file 6). Overall, in five out of seven patients
we sequenced, there were coding region nonsynonymous
SNVs, frameshift indels, and gross chromosomal deletions
targeting CD58 and B2M genes, suggesting that escaping
immune surveillance via mutations in key genes, such as
CD58 and B2M, may represent a common relapse strategy.
Two other deleted genes, ARHGEF7 and PLCB2, are in-
volved in RAC1 activation and downstream effects [25-27].
Deletions of these two genes may impair RAC1-mediated
B-cell receptor signaling [28]. In addition, deletion of IL9R
may affect JAK-STAT signaling in response to IL9 [29],
which is another pathway important in normal B cells
and lymphomas [30].
Ultra-deep target resequencing of relapse-specific
mutations in diagnostic DLBCL with early-divergent mode
of relapse identified minor subclones
By tracing VDJ SHM, we identified two clonal evolution
scenarios of DLBCL relapse. We reasoned that the evo-
lution of genetic events in DLBCL should follow similar
patterns. In the case of relapse with an early-divergent
mode, it is expected based on VDJ SHM analysis that a
small subclone exists within the diagnosis tumor that
carries a portion of relapse-specific SNVs or indels,
which were not detected by whole exome sequencing
but may be identified through deeper sequencing. To
test this idea, we performed targeted re-sequencing of
a number of SNVs and indels in early-divergent pairs.
We obtained roughly two million sequencing reads for
each amplicon, which allowed us to detect minor allele
frequency of 0.001% with 20X sequencing depth. Indeed,
targeted re-sequencing revealed that relapse-specific SNVs
and indels could be found in a small number of cells at
diagnosis in the early-divergent cases. For example, patient
1 gained at relapse a non-synonymous SNV in the UBR4
gene (chr1:19519971, C >A) that produced a premature
stop codon. Targeted re-sequencing of this locus confirmed
this SNV in the relapse sample of this patient (1R1)
(Figure 4A). Interestingly, we observed a very small
portion of the tumor cells at diagnosis (1D) also car-
ried this SNV (Figure 4A). This small clone accounted
for 0.16% of the total diagnosis tumor population
(background C > A conversion within this amplicon
was 0.03% ± 0.03%). In addition, the genetic evolution
pattern of this SNV during relapse of patient 1 mir-
rored this patient’s VHDJH clonal evolution pattern
(Figure 4B). In another example, the relapse tumor of
pair 9 (15R) gained a frameshift indel within the B2M gene
(chr15:45003781–45003782). Target re-sequencing con-
firmed that 53% of the relapse sequencing reads car-
ried this specific indel (Figure 4C, 15R, left y-axis),
while 0.04% of the diagnosis population also carried
Figure 3 Summary of copy number alteration information. The inner circles represent the CNA of each sample pair. Red indicates copy
number gain, and blue indicates copy number loss.
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15D2, right y-axis; background indel rate 0.004 ± 0.010%).
Although we did not observe any subclone in the diag-
nosis sample carrying the same major relapse VHDJH
sequence, probably due to the difficulty of aligning
VHDJH sequencing reads (Figure 4D), ultra-deep tar-
get amplicon re-sequencing allowed us to detect this
relapse-causing subclone. Taken together, our results
further confirmed the existence of small relapse-causing
subclones in the diagnosis tumors of the early-divergent




1 117064566-117131520 1R3, 3R, 14R CD58
4 961371-967030 1R1, 2R, 13R DGKQ
13 111885580-111996434 1R1, 2R, 3R, 14R ARHGEF7
15 40594724-40628804 1R1, 3R, 15R PLCB2
X 155003966-155250615 3R, 13R, 15R VAMP7, IL9RCoding-region SNV changes reveal potential mechanisms
of DLBCL relapse
To further explore the potential mechanisms of DLBCL
relapse, we performed pathway enrichment analysis
[31] on genes where we observed gain of coding region
nonsynonymous SNVs in relapse samples (false discovery
rate <10%; Figure 5). Pathway analysis revealed several
interesting characteristics of DLBCL relapse. First, relapse
samples in both groups gained additional mutations in
genes that regulate apoptosis (GO:0006915). Many of these
additional mutated genes are pro-apoptotic, such asples
Function in B cells
Genetically inactivated in DLBCL to escape immune recognition [24]
Not known
Guanine nucleotide exchange factor for RAC1 GTPases that
plays an important role in mature B-cell development [25]
Activated by RAC1 to modulate Ca2+ signaling [26]
IL9R activates JAK-STAT signaling in response to IL9 [29]
Figure 4 Targeted resequencing of relapse-specific mutations in diagnostic DLBCL. (A) Resequencing of UBR4 SNV (chr1:19519971, C > A)
in pair 1D and 1R1. The allele frequencies of the reference sequences and the SNV in both samples 1D and 1R1 are shown. (B) Comparison of
the clonal evolution pattern represented by the dominant VHDJH subclone (filled square) and the genetic evolution pattern indicated by the UBR4
SNV (filled circle) of pair 1. (C) Resequencing of B2M indel (chr15:45003781–45003782) in patient pair 9 (15D1, 15D2, and 15R). (D) Comparison of
the clonal evolution pattern and the genetic evolution pattern of patient pair 9.
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tumors to develop, tumor cells might need to acquire
extra survival advantages. Second, relapse samples
gained mutations in transmembrane receptor tyrosine
kinases (GO:0004714), among which were EPHB2 and
EPHB6, family members of the ephrin receptors,
which are involved in cell-cell signaling. Third, late-
divergent relapse samples gained more mutations in
genes that are involved in calcium channel activity
(GO:0005262) and p53 binding (GO:0002039). Inter-
estingly, calcium signals play a critical role in B-celldevelopment and functions, and are regulated by
many signaling pathways, including B-cell receptor
signaling [32]. Our data further suggest that DLBCL
tumors with defects in calcium flux regulation may be
resistant to current therapy and prone to relapse. Finally,
a recent report by Xu-Monette et al. [33] demonstrated
that patients with p53 mutations had worse overall and
progression-free survival compared with those without.
Our data now suggest that DLBCL relapse patients with
mutations in p53 functional partners may also have simi-
lar outcomes.
Figure 5 Pathway analysis on genes with coding-region SNVs revealing interesting characteristics of the early- and late-divergent
relapse modes. PAGE (Pathway Analysis of Gene Expression) pathway enrichment analysis was performed on gained SNV genes specific to either
late-divergent pairs or early-divergent pairs. The enriched functional groups are listed with a heat map representing the degree of enrichment.
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mutations of DLBCL
Exome sequencing data on paired diagnosis and relapse
samples in the early-divergent evolution mode provide
us with an opportunity to study the early events in lym-
phomagenesis. We reasoned that mutations that occurred
in both diagnosis and relapse tumors have been acquired
early in the life of these tumors and could have acted as
early 'driver' or 'facilitator' mutations that initiate tumori-
genesis. We observed that in all three divergent pairs,
histone-modifying enzymes were mutated in both relapse
and diagnosis tumors (Additional file 8). For example, we
detected KMT2D and SETDB1 mutations in both relapse
and diagnosis tumors of pair 1, KMT2D mutations in pair 2,
and EP300 mutations pair 9. The frequencies of all of these
SNVs were comparable between the diagnosis and relapse
samples within the same pair (Additional file 8). In pair 2,
we had limited amounts of germline tissue at our dis-
posal and performed Sanger sequencing to confirm
that KMT2D mutation is not found in germline DNA
(Figure S11 in Additional file 3). These observations
suggested that mutations of histone modifiers could
act as an early event to establish an aberrant epigenetic
landscape in tumor-initiating cells and eventually drive the
malignant transformation. Moreover, we observed that re-
lapse samples in the early-divergent group gained additional
coding region SNVs in epigenetic modifiers; that is, sample
1R2 in pair 1 gained a TET2 SNV, sample 2R of pair 2
gained a SNV in EP300, and sample 15R of pair 9 gained a
BRD4 SNV (Additional file 4). These findings suggested that
epigenetic modifiers were further targeted during the relapse
process, resulting in potential chemoresistance and other
features that facilitate the development of relapse disease.
Discussion
When cancer patients relapse, their tumors often be-
come more aggressive, chemoresistant, and refractory
to treatment. The molecular pathogenesis of cancer relapse
is largely unknown due to challenges in examining tumorheterogeneity and clonal evolution between diagnosis and
relapse tumors in many types of cancers. Here we sought
to investigate the molecular mechanisms of DLBCL relapse,
utilizing the ability to track tumor heterogeneity and clonal
evolution through examination of VHDJH rearrangements
and SHM, as well as exome sequencing. To exhaustively
catalog the VHDJH repertoires of the tumor samples, we
adapted next-generation sequencing technology to se-
quence the IgVDJ rearrangements in great depth. This
approach has been successfully used in other studies to
examine human antibody repertoires [12,34,35], assess
clonal heterogeneity in B-ALL or chronic lymphocytic
leukemia [10,36,37], or monitor minimal residual dis-
ease in chronic lymphocytic leukemia [38]. We observed
a wide range of VDJ heterogeneity within diagnosis DLBCL
samples, but no significant differences in this between the
paired diagnosis and relapse tumors, suggesting that tumor
heterogeneity was preserved after disease progression due
to either the incomplete eradication of the diagnosis tumor
or ongoing VDJ rearrangement during relapse. However,
we could not completely rule out the possibility of non-
tumor B-cell contamination.
Because DLBCL is a clonal disease, we decided to focus
on the major VHDJH rearrangement clone. We found that,
with one exception, the majority of the diagnosis and
tumor pairs had the same major VHDJH rearrangement,
indicating they were clonally related, even when the re-
lapse tumors developed more than 5 years after the diag-
nosis tumor, similar to what has been reported before
[39]. We identified two distinct patterns of SHM amongst
the diagnosis-relapse sample pairs, suggesting two modes
of relapse disease development. In addition, exome se-
quencing on several sample pairs with different SHM pat-
terns also revealed profound evidence to further support
the idea that there are two discrete pathogenesis mecha-
nisms of DLBCL relapse. In the late-divergent mode, the
diagnosis-relapse pairs exhibited: 1) almost identical SHM
frequency and distribution of the subclones that they
clustered together in the phylogenetic tree; 2) highly
Jiang et al. Genome Biology 2014, 15:432 Page 13 of 17
http://genomebiology.com/2014/15/8/432overlapping SNV profiles with additional gained SNVs
in the relapse samples; 3) ongoing genomic instability
that resulted in CNA in relapse samples. In the early-
divergent mode, the diagnosis-relapse pairs exhibited:
1) vastly different distribution of SHM, which led to
segregation in the phylogenetic tree; and 2) less over-
lapping SNV profiles in which relapse tumors 'gained'
and 'lost' similar numbers of SNVs compared with
diagnosis tumors. Taken together, our results suggest
that DLBCL relapse develops either from a late sub-
clone within the diagnosis tumor, which shares the ma-
jority of the mutations with the major diagnosis clone
(late-divergent mode), or from a highly diverged, rela-
tively early minor subclone within the diagnosis tumor
that may share some tumor-initiating (driver) muta-
tions with the major diagnosis clone but may acquire
additional independent facilitating (facilitator) muta-
tions important for lymphomagenesis at a later time
point during relapse (early-divergent mode) (Figure 6).
Indeed, by performing ultra-deep targeted re-sequencing
of SNVs and indels gained in relapse samples, we con-
firmed in the diagnostic tumors the presence of minor
subclones that already carry some of the same mutations
as the relapse tumors in the early divergent scenario. The
frequency of the diagnosis tumor cells harboring relapse-
specific SNVs and indels was similar to the frequency of
diagnosis cells carrying the same major relapse VHDJH se-
quences, implying that these subclones indeed are the pre-
cursors of the final relapse tumors. Taken together, our
data suggest that a small subpopulation of the lymphoma
cells may survive chemotherapy, possibly due to acquisi-
tion of additional mutations that confer chemotherapy re-
sistance or 'hiding' of the tumor cells in protective cellular
milieu (for example, BM). This subclone may then acquire
additional facilitator mutations important for full gener-
ation of relapse at a later time point. A similar scenario is
likely to operate in the late-divergent scenario. Ultra-deep
targeted re-sequencing of relapse-specific alterations will
be useful to further investigate the size of relapse precur-
sor subclones present in the diagnostic tumors in those
cases. Recently, Pasqualucci et al. [40] demonstrated that
follicular lymphomas (FLs) and transformed FLs evolve
via linear or divergent evolution patterns by examining FL
exomes. By characterizing both the immunoglobulin gene
and the rest of the genome, we showed similar evolution
patterns for DLBCL relapse, suggesting that these evolu-
tion patterns may be common to lymphoid malignancies.
In recent years, several studies have examined primary
(non-relapse) DLBCL exomes and discovered many re-
current mutations [17-20,41]. However, with one excep-
tion, that is, EZH2 [21], the lack of knowledge about
how these mutations lead to disease development hinders
the development of effective targeted therapies. To date,
it is still unclear whether these mutations are 'driver'mutations that initiate the malignant transformation,
'facilitator' mutations that promote disease progression,
or just merely 'passenger' mutations that have no effects
on the disease pathogenesis. The early-divergent mode
of tumor evolution uncovered here provided us with an
opportunity to identify early driver mutations in lym-
phomagenesis via 'ancestral' tumor reconstruction. Indeed,
common mutations between the diagnosis and relapse tu-
mors are likely to have been acquired early and constitute
potentially disease-initiating mutations that are acquired by
the tumors at the earliest stage. By comparing and contrast-
ing exomes of diagnosis and relapse samples, we found that
epigenetic modifiers, such as EP300, KMT2D, and SETDB1,
were mutated in both diagnosis and relapse tumors, sug-
gesting that these mutations could be the driver mutations
of DLBCL. Similarly, Green et al. [42] also reported that
CREBBP mutations were early 'driver' mutations in FL be-
cause they were found in the CD20 subpopulations in both
diagnosis and relapse FLs, while KMT2D mutations were
likely later 'accelerators' in FL since they were only found in
one of the subpopulations. Moreover, KMT2D, CREBBP,
and EP300 are among the most frequently mutated genes
in DLBCL and FL [17-20,41]. Therefore, we hypothesize
that mutations within epigenetic modifiers may act as early
driver events in lymphomagenesis and help establish an
aberrant epigenetic environment suitable for subsequent
malignant transformation. Further experiments modeling
these mutations are needed to elucidate their functions in
driving lymphomagenesis. In addition, we observed relapse
samples of the early-divergent mode gained extra mutations
in epigenetic modifiers. A similar phenomenon has also
been observed in other relapse diseases, such as CREBBP
and SETD2 mutations enriched in relapse B-ALL [43,44].
All together, these observations suggest that mutations in
epigenetic modifiers may be responsible for the chemore-
sistance feature of these tumors allowing them to survive
or escape initial therapies and develop into relapse tumors.
Moreover, through our mutation analysis, we identified sev-
eral pathways that may be involved in the relapse process.
These pathways include apoptosis regulation, transmem-
brane receptor tyrosine kinases, calcium channel activity
and p53 binding. Several these pathway genes and their
family members have been implicated in lymphomagenesis
previously. For example, relapse samples gained mutations
in transmembrance receptor tyrosine kinase genes EPHB2
and EPHB6, whose family member EPHA7 encodes a
known soluble tumor suppressor for FL [45]. Our re-
sults suggest that this family of tyrosine kinases may
play an additional role in preventing DLBCL relapse.
Moreover, because of the importance of calcium-dependent
regulation of NFAT and NF-κB activities in the determin-
ation of cell-fate choice of B cells during humoral immune
responses, and the chronic activation of B-cell receptor
signaling and elevated calcium signaling in aggressive
Figure 6 A model of early- and late-divergent modes of DLBCL relapse. In both modes, the early B lymphoma precursors arise from normal
B cells that sustain key genetic lesions, such as mutations occurring at epigenetic modifying enzymes, that is, EP300, KMT2D, and SETDB1. In the
late-divergent mode (top panel), after acquiring additional facilitator mutations, early B lymphoma precursors develop into DLBCL-containing
subclones that have similar but slightly different SHM profiles (indicated by different shades of red) due to ongoing SHM. After treatment, one or few
subclones survive and develop into relapse disease, potentially by acquiring additional mutations. In the early-divergent mode (bottom panel), early B
lymphoma precursor cells progress into initial DLBCL-containing subclones that have similar SHMs (indicated by different shades of red) and one or
few minor subclones (depicted by blue) that have unique SHM profiles vastly different from the subclones of the major diagnostic clone (the red ones),
indicating divergence during clonal expansion of the tumor. This minor clone later survives or escapes chemotherapy, and develops into a relapse
tumor that has a diverged subclonal origin from the diagnosis tumor (blue versus red).
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to further investigate the role of this pathway in the
DLBCL relapse process and develop targeted therapy
against this pathway to treat relapse DLBCL. Indeed,
targeting B-cell receptor signaling components has
already been shown to be beneficial for relapsed/refractory
B-cell malignancies [47].
Conclusions
Using ultra-deep sequencing of the rearranged IgH locus
and the exomes of diagnosis and relapse DLBCL tumor
pairs, we identified two distinct evolutionary scenarios
that lead to relapse. In one scenario, the relapse clone
evolves directly from the main diagnosis clone via the
acquisition of additional relapse-driving mutations. We
termed this scenario the 'late-divergent' mode. In the
other scenario, diagnosis and relapse evolve in parallel
from a common, early progenitor cell and carry very
different patterns of somatic mutations. We named
this scenario the 'early-divergent' mode. Our data fur-
ther suggest that mutations within epigenetic modifiers
could occur early in lymphomagenesis and act as the
driving events. We also identified frequent genetic alter-
ations in immune surveillance genes (B2M and CD58),
suggesting immune escape contributes to lymphoma
relapse. Therefore, our study presents important evidence
for the first time that DLBCL relapse may result from
multiple different pathogenesis mechanisms, providingrationales for the design of distinct therapies for each
mechanism. Moreover, this study highlights the urgent
need for understanding the roles of epigenetic modifier
and immune escape mutations in driving lymphoma-
genesis and the relapse phenotype.
Materials and methods
Case selection
Diagnosis and relapse DLBCL cases were selected from
a search of the database of the Department of Pathology
and Laboratory Medicine at Weill Cornell Medical College
and Department of Pathology at Singapore General Hospital.
Information regarding clinical history and presentation,
therapy and follow-up was obtained from electronic clinical
records. All patients provided written consent for use of tis-
sues samples for research, in accordance with the Declar-
ation of Helsinki regulations of the protocols approved by
the Institutional Review Board of Weill Cornell Medical
College, New York, USA (IRB # 0107004999), and by
SingHealth Services, Singapore (IRB # 2006/036/B).
DNA extraction
DNA was extracted from either frozen solid tissue sec-
tions or formalin-fixed paraffin-embedded tissue sec-
tions. Frozen tissue samples were first digested overnight
with 0.5 mg/ml Proteinase K and 0.625% SDS in 4 ml
nucleic lysis buffer at 37°C. After digestion, 1 ml of satu-
rated NaCl was added to the samples and samples were
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for 15 minutes. Supernatant was transferred to a new tube
and mixed with two volumes of room temperature 100%
ethanol. DNA was precipitated by centrifugation at max-
imum speed for 30 minutes, washed twice with 70% etha-
nol, and finally dissolved in TE or nuclease-free water
overnight at room temperature. Formalin-fixed paraffin-
embedded samples were de-paraffined first by incubating
in Xylene at room temperature for 10 minutes twice
followed by incubating with 100% ethanol at room
temperature for 10 minutes twice. Samples were then
allowed to air-dry and then incubated with 0.5 mg/ml
Proteinase K in 1X PCR buffer overnight at 37°C followed
by 95°C for 10 minutes to heat inactivate Proteinase K.
VHDJH sequencing
The IgVHFR1 VDJ junctions were amplified using mix 2
of the Somatic Hypermutation Assay from InvivoScribe
Technologies (San Diego, CA, U.S.A.). The IgVHFR2
VDJ junctions were amplified using Tube B of IGH
Gene Clonality Assay from InvivoScribe Technologies.
PCR products were resolved on 2% agarose gel and the
major product of the appropriate size was purified by
using a QIAGEN MiniElute Gel Extraction kit (Valencia,
CA, U.S.A.). Sequencing libraries were constructed from
the purified PCR product by using Illumina TruSeq DNA
Sample Preparation Kit v2 (San Diego, CA, U.S.A.). Each
sample was tagged with a unique index. For each MiSeq
sequencing run, five VDJ samples were mixed together
at 7 μM with 50% PhiX spike-in to ensure the complexity
of the run.
Exome sequencing
Exome sequencing samples were prepared using the
Aglient SureSelectXT Human All Exon 50 MB Target
Enrichment System for Illumina Paired-End Sequencing
Library kit. PE75 sequencing was performed on Illumina
HiSeq 2000. For sample 1, we sequenced all three relapse
samples that were obtained at three separate biopsy sites,
and analyzed them independently.
VHDJH analysis pipeline
Paired-end sequence reads were mapped against a human
IGH reference database available from the IMGT website
[9] using a modified nucleotide blast search. Sequences
without a hit in all three V, D and J regions were filtered
out and reads with all three regions present were
counted for the number of each unique rearrangement.
These counts were then ranked for each sample and the
major rearrangements were then aligned against their
corresponding dominant VHDJH sequences. To perform
phylogenetic analysis, within each sample we selected
the subclones of the major VHDJH rearrangement that
had at least 10 sequencing counts and a minimum 80%sequence similarity to the reference germline VDJ sequence.
We then ranked these subclones in the diagnosis sample
based on their similarity to the SHM profile of the respective
relapse sample, and vice versa. The top 10 ranked subclones
along with the 10 most abundant clones and a random
selection of minor subclones from each diagnosis and re-
lapse samples within each pair were then re-aligned using
the multiple sequence alignment tool Clustalw to build a
neighbor-joining tree by using the R package 'ape' [13]. The
tree coordinates alongside the corresponding frequencies
for each alignment were drawn using a custom script.
Exome analysis pipeline
SNV discovery
Short sequencing reads were aligned to human genome
assembly GRCh37/hg19 using the BWA aligner [48].
Duplicated paired reads were filtered and variant detection
was performed as previously described [14-16]. Novel cod-
ing region SNVs (not present in SNP132) were further fil-
tered according to sequencing depth (≥20X) and variant
percentage (≥25%). To analyze the mutational status change
(gain or loss) within each diagnosis and relapse pair,
we compared the variant ratio of each novel coding
SNV between the diagnosis and relapse samples and
estimated the statistical significance of the difference
by using a Chi-square tested corrected with multiple
hypothesis testing (Benjamini-Hochberg corrected P < 0.1).
To obtain the list of common novel coding region
SNVs, we took those SNVs that did not show a signifi-
cant different variant ratio between the diagnosis and
relapse samples (corrected P > 0.1) and selected the
ones that were mutated in at least two non-Hodgkin’s
lymphoma patients in other studies.
CNA segment calling
In order to call CNA segments, aligned short sequencing
reads were used to generate log2 ratios between the
diagnosis and relapse samples for each patient using an
in-house program, CNVseeqer. The log2 ratios represent
the number of reads mapped to an exon in the relapse
sample compared with a diagnosis sample. Log2 ratios
of exons that had more than 100 total reads between
both the diagnosis and relapse samples were smoothed
and then used for segmentation identification using a
circular binary segmentation algorithm DNAcopy in R [22].
Segments with a standard deviation >1.5 were defined as
CNA segments. Segments with a mean log2 ratio >0.3 were
categorized as copy number gain loci, while segments
with a mean log2 ratio < −0.3 were categorized as copy
number loss loci.
Data deposition
All exome-sequencing raw data files have been depos-
ited into NCBI database BioProject PRJNA240335 [49].
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sequencing and targeted resequencing of the UBR4
and B2M loci, have been deposited into NBCI database
BioProject PRJNA240336 [50].
Additional files
Additional file 1: Table S1. Clinical information of the patient samples
used in this study.
Additional file 2: Table S2. Sequencing run metrics.
Additional file 3: Supplementary figures.
Additional file 4: Table S3. Coding region nonsynonymous SNVs
gained or lost in relapse samples.
Additional file 5: Table S4. Sanger validation results on selected
nonsynonymous SNVs gained in relapse samples.
Additional file 6: Table S5. Coding region indels gained in relapse
samples.
Additional file 7: Table S6. Gained copy number alterations in
relapse samples.
Additional file 8: Table S7. Sequencing results of epigenetic modifier
mutations in sample pairs 1, 2, and 9.
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